• Price (EUR)0.5252
  • Today's Change-0.013 / -2.49%
  • Shares traded0.00
  • 1 Year change-70.66%
  • Beta--
Data delayed at least 15 minutes, as of Jul 04 2022 15:01 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cybin Inc. is a Canada-based biopharmaceutical company, working with a network of partners and scientists to create therapeutics for patients to address a multitude of mental health issues. The Company operates in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. The Company’s products in pipeline include EMBARK, Kernel Flow, CYB003 (Deuterated Psilocybin Analog), CYB004 (Deuterated Dimethyltryptamine), and CYB005 (Phenethylamine Derivative). EMBARK is a Psilocybin for mental distress in frontline healthcare workers. Its subsidiaries include Cybin Corp., Natures Journey Inc., Serenity Life Sciences Inc., Cybin US Holdings Inc., Adelia Therapeutics Inc. and Cybin IRL Limited.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-67.63m
  • Incorporated2016
  • Employees50.00
  • Location
    Cybin Inc100 King Street West, Suite 5600TORONTO M5X 1C9CanadaCAN
  • Phone+1 (604) 806-0626
  • Fax+1 (604) 806-0626
  • Websitehttps://www.cybin.com
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.